Search

Your search keyword '"Guckenberger M"' showing total 93 results
Start Over Author "Guckenberger M" Journal international journal of radiation oncology, biology, physics
93 results on '"Guckenberger M"'

2. Post-Operative Stereotactic Radiotherapy for Resected Brain Metastases: Results of the Multicenter Analysis (AURORA) of the German Working Group "Stereotactic Radiotherapy"

Author

Bernhardt, D., Peeken, J.C., Kehl, V., Eitz, K., Guckenberger, M., Andratschke, N., Mayinger, M.C., Lindel, K., Dieckmann, K., El Shafie, R., Debus, J., Riesterer, O., Rogers, S., Blanck, O., Wolff, R., Grosu, A., Bilger, A., Henkenberens, C., Schulze, K., Gani, C., Müller, A.C., Radlanski, K., Janssen, S., Ferentinos, K., and Combs, S.E.

Published
2023
Full Text
View/download PDF

7. Contouring Quality and Adherence to EORTC-based Protocol Guidelines in the Randomized Phase III SAKK 09/10 Trial for Postoperative Prostate Cancer Radiotherapy: Implications for Treatment Quality and Future Clinical Trials

Author

Beck, M., Sassowsky, M., Schär, S., Mathier, E., Halter, M., Zwahlen, D.R., Hölscher, T., Arnold, W., Polat, B., Hildebrandt, G., Mueller, A.C., Putora, P.M., Papachristofilou, A., Sumila, M., Zaugg, K., Guckenberger, M., Ost, P., Aebersold, D.M., Ghadjar, P., and Dal Pra, A.

Published
2020
Full Text
View/download PDF

14. International Collaborative Propensity-Based Matched Pair Analysis of Operable Early Stage Lung Ancer Patients Treated with Stereotactic Body Radiation Therapy Compared to Resection: Differences in Recurrence and Survival with Prolonged Follow-Up

Author

Grills, I.S., Lee, K.C., Jr., Belderbos, J., Hope, A.J., Giuliani, M.E., Guckenberger, M., Mantel, F., Werner-Wasik, M., Peulen, H.M., Sonke, J.J., Yan, D., Hymas, R.V., Jr., Caruso, A., Abro, N., Johnson, M.C., Abbott, E., Ye, H., and Welsh, R.

Published
2017
Full Text
View/download PDF

20. Results of the Planning Comparison Study SBRT of NSCLC

Author

Moustakis, C., Ernst, I., Kittel, C., Eich, H., Krieger, T., Duma, M., Oechsner, M., Ganswindt, U., Heinz, C., Alheit, H., Blank, H., Nestle, U., Wiehle, R., Kornhuber, C., Ostheimer, C., Petersen, C., Albers, D., Pollul, G., Baus, W.W., Altenstein, G., Blanck, O., Beckers, E., Sterzing, F., Kretschmer, M., Seegenschmiedt, H., Maass, T., Droege, S., Wolf, U., Schoeffler, J., Thiele, M., Ciernik, I.F., Ebrahimi, F., and Guckenberger, M.

Published
2015
Full Text
View/download PDF

32. Potential of adaptive radiotherapy to escalate the radiation dose in combined radiochemotherapy for locally advanced non-small cell lung cancer.

Author

Guckenberger M, Wilbert J, Richter A, Baier K, Flentje M, Guckenberger, Matthias, Wilbert, Juergen, Richter, Anne, Baier, Kurt, and Flentje, Michael

Abstract

Purpose: To evaluate the potential of adaptive radiotherapy (ART) for advanced-stage non-small cell lung cancer (NSCLC) in terms of lung sparing and dose escalation. Methods and Materials: In 13 patients with locally advanced NSCLC, weekly CT images were acquired during radio- (n=1) or radiochemotherapy (n=12) for simulation of ART. Three-dimensional (3D) conformal treatment plans were generated: conventionally fractionated doses of 66 Gy were prescribed to the planning target volume without elective lymph node irradiation (Plan_3D). Using a surface-based algorithm of deformable image registration, accumulated doses were calculated in the CT images acquired during the treatment course (Plan_4D). Field sizes were adapted to tumor shrinkage once in week 3 or 5 and twice in weeks 3 and 5. Results: A continuous tumor regression of 1.2% per day resulted in a residual gross tumor volume (GTV) of 49%±15% after six weeks of treatment. No systematic differences between Plan_3D and Plan_4D were observed regarding doses to the GTV, lung, and spinal cord. Plan adaptation to tumor shrinkage resulted in significantly decreased lung doses without compromising GTV coverage: single-plan adaptation in Week 3 or 5 and twice-plan adaptation in Weeks 3 and 5 reduced the mean lung dose by 5.0%±4.4%, 5.6%±2.9% and 7.9%±4.8%, respectively. This lung sparing with twice ART allowed an iso-mean lung dose escalation of the GTV dose from 66.8 Gy±0.8 Gy to 73.6 Gy±3.8 Gy. Conclusions: Adaptation of radiotherapy to continuous tumor shrinkage during the treatment course reduced doses to the lung, allowed significant dose escalation and has the potential of increased local control. [ABSTRACT FROM AUTHOR]

Published
2011
Full Text
View/download PDF

33. Dose-response relationship for image-guided stereotactic body radiotherapy of pulmonary tumors: relevance of 4D dose calculation.

Author

Guckenberger M, Wulf J, Mueller G, Krieger T, Baier K, Gabor M, Richter A, Wilbert J, Flentje M, Guckenberger, Matthias, Wulf, Joern, Mueller, Gerd, Krieger, Thomas, Baier, Kurt, Gabor, Manuela, Richter, Anne, Wilbert, Juergen, and Flentje, Michael

Abstract

Purpose: To evaluate outcome after image-guided stereotactic body radiotherapy (SBRT) for early-stage non-small-cell lung cancer (NSCLC) and pulmonary metastases. Methods and Materials: A total of 124 patients with 159 pulmonary lesions (metastases n = 118; NSCLC, n = 41; Stage IA, n = 13; Stage IB, n = 19; T3N0, n = 9) were treated with SBRT. Patients were treated with hypofractionated schemata (one to eight fractions of 6-26 Gy); biologic effective doses (BED) to the clinical target volume (CTV) were calculated based on four-dimensional (4D) dose calculation. The position of the pulmonary target was verified using volume imaging before all treatments. Results: With mean/median follow-up of 18/14 months, actuarial local control was 83% at 36 months with no difference between NSCLC and metastases. The dose to the CTV based on 4D dose calculation was closely correlated with local control: local control rates were 89% and 62% at 36 months for >100 Gy and <100 Gy BED (p = 0.0001), respectively. Actuarial freedom from regional and systemic progression was 34% at 36 months for primary NSCLC group; crude rate of regional failure was 15%. Three-year overall survival was 37% for primary NSCLC and 16% for metastases; no dose-response relationship for survival was observed. Exacerbation of comorbidities was the most frequent cause of death for primary NSCLC. Conclusions: Doses of >100 Gy BED to the CTV based on 4D dose calculation resulted in excellent local control rates. This cutoff dose is not specific to the treatment technique and protocol of our study and may serve as a general recommendation. [ABSTRACT FROM AUTHOR]

Published
2009
Full Text
View/download PDF

47. Adaptive radiotherapy for locally advanced non-small-cell lung cancer does not underdose the microscopic disease and has the potential to increase tumor control.

Author

Guckenberger M, Richter A, Wilbert J, Flentje M, Partridge M, Guckenberger, Matthias, Richter, Anne, Wilbert, Juergen, Flentje, Michael, and Partridge, Mike

Abstract

Purpose: To evaluate doses to the microscopic disease (MD) in adaptive radiotherapy (ART) for locally advanced non-small-cell lung cancer (NSCLC) and to model tumor control probability (TCP).Methods and Materials: In a retrospective planning study, three-dimensional conformal treatment plans for 13 patients with locally advanced NSCLC were adapted to shape and volume changes of the gross tumor volume (GTV) once or twice during conventionally fractionated radiotherapy with total doses of 66 Gy; doses in the ART plans were escalated using an iso-mean lung dose (MLD) approach compared to non-adapted treatment. Dose distributions to the volumes of suspect MD were simulated for a scenario with synchronous shrinkage of the MD and GTV and for a scenario of a stationary MD despite GTV shrinkage; simulations were performed using deformable image registration. TCP calculations considering doses to the GTV and MD were performed using three different models.Results: Coverage of the MD at 50 Gy was not compromised by ART. Coverage at 60 Gy in the scenario of a stationary MD was significantly reduced from 92% ± 10% to 73% ± 19% using ART; however, the coverage was restored by iso-MLD dose escalation. Dose distributions in the MD were sufficient to achieve a TCP >80% on average in all simulation experiments, with the clonogenic cell density the major factor influencing TCP. The combined TCP for the GTV and MD was 19.9% averaged over all patients and TCP models in non-adaptive treatment with 66 Gy. Iso-MLD dose escalation achieved by ART increased the overall TCP by absolute 6% (adapting plan once) and by 8.7% (adapting plan twice) on average. Absolute TCP values were significantly different between the TCP models; however, all TCP models suggested very similar TCP increase by using ART.Conclusions: Adaptation of radiotherapy to the shrinking GTV did not compromise dose coverage of volumes of suspect microscopic disease and has the potential to increase TCP by >40% compared with radiotherapy planning without ART. [ABSTRACT FROM AUTHOR]

Published
2011
Full Text
View/download PDF

50. Practice recommendations for risk-adapted head and neck cancer radiotherapy during the COVID-19 pandemic

Author

Johannes A. Langendijk, Jordi Giralt, Matthias Guckenberger, Jørgen Johansen, John Waldron, Shlomo A. Koyfman, Danielle N. Margalit, Jimmy J. Caudell, Panagiotis Balermpas, Ying J. Hitchcock, Johannes H.A.M. Kaanders, Sandro V. Porceddu, Jonathan J. Beitler, Pierre Blanchard, Yoke Lim Soong, Michelle Mierzwa, June Corry, David M. Brizel, Wilfred Budach, David A. Palma, Sue S. Yom, Adam S. Garden, Vincent Grégoire, Nancy Y. Lee, Mererid Evans, Renzo Corvò, Ying Sun, Quynh-Thu Le, Kevin J. Harrington, Paul M. Harari, Juliette Thariat, David J Thomson, Institut Català de la Salut, [Thomson DJ] Department of Clinical Oncology, The Christie NHS Foundation Trust, Manchester, and the Division of Cancer Sciences, The University of Manchester, UK. [Palma D] Division of Radiation Oncology, Western University, London, Canada. [Guckenberger M, Balermpas P] Department of Radiation Oncology, University Hospital Zurich, University of Zurich, Zurich, Switzerland. [Beitler JJ] Department of Radiation Oncology, Emory University, Atlanta, Georgia. [Blanchard P] Department of Radiation Oncology, Gustave Roussy Cancer Center, Villejuif, France. [Giralt J] Servei d’Oncologia Radioteràpica, Vall d'Hebron Hospital Universitari, Barcelona, Spain, Vall d'Hebron Barcelona Hospital Campus, Guided Treatment in Optimal Selected Cancer Patients (GUTS), and Damage and Repair in Cancer Development and Cancer Treatment (DARE)

Subjects
Cancer Research, medicine.medical_treatment, Delphi method, Otros calificadores::Otros calificadores::/radioterapia [Otros calificadores], Environment and Public Health::Public Health::Disease Outbreaks::Epidemics::Pandemics [HEALTH CARE], Coll - Càncer - Radioteràpia, Medical Oncology, COVID-19 (Malaltia), 030218 nuclear medicine & medical imaging, 0302 clinical medicine, Neoplasms::Neoplasms by Site::Head and Neck Neoplasms [DISEASES], Pandemic, Health care, virosis::infecciones por virus ARN::infecciones por Nidovirales::infecciones por Coronaviridae::infecciones por Coronavirus [ENFERMEDADES], Outpatient clinic, Pandèmia de COVID-19, 2020, Viral, Societies, Medical, Risk management, Cancer, Response rate (survey), Radiation, Other subheadings::Other subheadings::/radiotherapy [Other subheadings], Virus Diseases::RNA Virus Infections::Nidovirales Infections::Coronaviridae Infections::Coronavirus Infections [DISEASES], Hematology, Other Physical Sciences, Cap - Càncer - Radioteràpia, ambiente y salud pública::salud pública::brotes de enfermedades::epidemias::pandemias [ATENCIÓN DE SALUD], Oncology, Radiology Nuclear Medicine and imaging, Head and Neck Neoplasms, 030220 oncology & carcinogenesis, Practice Guidelines as Topic, SQUAMOUS-CELL CARCINOMA, Coronavirus Infections, Rare cancers Radboud Institute for Health Sciences [Radboudumc 9], medicine.medical_specialty, Consensus, Pneumonia, Viral, Clinical Sciences, Oncology and Carcinogenesis, MEDLINE, Article, Betacoronavirus, 03 medical and health sciences, Clinical Research, Medical, medicine, Humans, neoplasias::neoplasias por localización::neoplasias de cabeza y cuello [ENFERMEDADES], Radiology, Nuclear Medicine and imaging, Oncology & Carcinogenesis, Dental/Oral and Craniofacial Disease, Pandemics, SARS-CoV-2, business.industry, Prevention, COVID-19, Pneumonia, Radiation therapy, Good Health and Well Being, Family medicine, business, Societies
Abstract

Càncer de cap i coll; Radioteràpia; Coronavirus SARS-CoV-2; COVID-19; 2019-nCoV Cáncer de cabeza y cuello; Terapia de radiación; Coronavirus SARS-CoV-2; COVID-19; 2019-nCoV Head and Neck Cancer; Radiation Therapy; Coronavirus SARS-CoV-2; COVID-19; 2019-nCoV Purpose Because of the unprecedented disruption of health care services caused by the COVID-19 pandemic, the American Society of Radiation Oncology (ASTRO) and the European Society for Radiotherapy and Oncology (ESTRO) identified an urgent need to issue practice recommendations for radiation oncologists treating head and neck cancer (HNC) in a time of limited resources and heightened risk for patients and staff. Methods and Materials A panel of international experts from ASTRO, ESTRO, and select Asia-Pacific countries completed a modified rapid Delphi process. Topics and questions were presented to the group, and subsequent questions were developed from iterative feedback. Each survey was open online for 24 hours, and successive rounds started within 24 hours of the previous round. The chosen cutoffs for strong agreement (≥80%) and agreement (≥66%) were extrapolated from the RAND methodology. Two pandemic scenarios, early (risk mitigation) and late (severely reduced radiation therapy resources), were evaluated. The panel developed treatment recommendations for 5 HNC cases. Results In total, 29 of 31 of those invited (94%) accepted, and after a replacement 30 of 30 completed all 3 surveys (100% response rate). There was agreement or strong agreement across a number of practice areas, including treatment prioritization, whether to delay initiation or interrupt radiation therapy for intercurrent SARS-CoV-2 infection, approaches to treatment (radiation dose-fractionation schedules and use of chemotherapy in each pandemic scenario), management of surgical cases in event of operating room closures, and recommended adjustments to outpatient clinic appointments and supportive care. Conclusions This urgent practice recommendation was issued in the knowledge of the very difficult circumstances in which our patients find themselves at present, navigating strained health care systems functioning with limited resources and at heightened risk to their health during the COVID-19 pandemic. The aim of this consensus statement is to ensure high-quality HNC treatments continue, to save lives and for symptomatic benefit.

Published
2020

Catalog

Books, media, physical & digital resources
See catalog results